

AACR Special Conference Tumor Immunology and Immunotherapy


October 21-24, 2022 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients.

Relationships are abbreviated as follows: E, Employment; FO, Fiduciary Officer; IC, Independent Contractor; S, Stock; SO, Stock Option; OS, Other Securities; OBO, Other Business Ownership; GC, Grant/Contract; T, Travel; GI, Gift; P, Patent; TM, Trademark, C, Copyright; OIP, Other Intellectual Property; O, Other

Last Name	First Name	All Relationships	Type	Role
Amit	Ido	No Relationships		Speaker
Arthur	Ronald	No Relationships		Staff
Blank	Christian	BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures, BMS, Novartis, NanoString, 4SC, Immagine BV and Signature Oncology, Patents (incl. submitted): WO 2021/177822 A1, N2027907, P091040NL2	IC, IC, IC, IC, IC IC, IC, IC, IC, IC, IC, GC, GC. GC, S, S, P	Speaker
Egeblad	Mikala	Vividion Therapeutics, Inc, Agios Pharmaceuticals, Inc., Insmmed, Inc.	IC, S, IC	Speaker
Gajewski	Thomas	Pyxis Oncology, Jounce Therapeutics, Merck, Pyxis Oncology, Adaptimmune, Bristol Myers Squibb Company, Pyxis Oncology, Samyang, FogPharma, Catalym, Allogene, Bicara, Jounce Therapeutics, Maia	S, IC, GC, GC, IC, GC, IC, IC, IC, IC, IC, IC, S, IC	Program Committee, Speaker
Galsky	Matthew	Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Merck, Basilea, Rappta Therapeutics, Genentech, Seattle Genetics, Inc., Dragonfly, Dracen, AstraZeneca, NuMab, Alligator, Astellas Pharma, Incyte Corporation, Janssen Biotech	IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC	Speaker
Greenbaum	Benjamin	Merck, Bristol-Meyers Squibb, Chugai Pharmaceuticals, PMV Pharma and Rome Therapeutics	IC, IC, IC, GC, IC, IC	Speaker
Guerriero	Jennifer	Immunitas Tx, Merck, KOWA COMPANY, LTD., Codagenix, AstraZeneca, Duke Street Bio	IC, GC, IC, IC, IC, IC	Speaker




AACR Special Conference Tumor Immunology and Immunotherapy

October 21-24, 2022 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Ho	Won Jin	Exelixis, SANOFI US SERVICES INC., Amgen, Standard BioTools	IC, GC, P, IC	Speaker
Li	Zihai	No Relationships		Speaker
Lipson	Evan	Bristol-Myers Squibb, CareDx, Eisai, Genentech, InstilBio, MacroGenics, Merck, Natera, Nektar, Novartis, Odonate Therapeutics, OncoSec, Pfizer, Rain Therapeutics, Regeneron, Sanofi	IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, GC, GC, GC, GC	Speaker
Luksza	Marta	Patent - Neoantigens and uses thereof for treating cancer	P	Speaker
Majzner	Robbie	Syncopation, Nkarta, Link Cell Therapies, Lyell	SO, IC, SO, SO	Speaker
Moran	Amy	Jackson Laboratory, Patent - Immune cells with reduced androgen receptor (AR)	OIP, P	Speaker
Moslehi	Javid	Myovant, Cytokinetics, AstraZeneca, Takeda Pharmaceutical Company, Bristol Myers Squibb Company, Amgen	IC, IC, IC, IC, IC, IC	Speaker
Munn	Lance	Bayer, Simbiosys	E, IC	Speaker
Nolan	Garry	No Relationships		Speaker
Post	Dean	No Relationships		Staff
Reschke	Robin	No Relationships		Speaker




AACR Special Conference Tumor Immunology and Immunotherapy

October 21-24, 2022 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Sharma	Padmanee	Enable Medicine, Akoya Biosciences, Xilis, Inc, LAVA Therapeutics, Trained Therapeutix Discovery, InterVenn Biosciences, Constellation, BioAlta LLC, Earli Inc., PBM Capital, Candel Therapeutics, PBM Capital, Earli Inc., Kite Pharma, Inc., Codiak Biosciences, Inc, Dragonfly Therapeutics, formerly called Equipoise Therapeutics Corporation, Lytix Biopharma, Hummingbird Bioscience, Infinity Pharmaceuticals Inc., Glympse Bio, Trained Therapeutix Discovery, Gilead Sciences Inc, Dragonfly Therapeutics, formerly called Equipoise Therapeutics Corporation, Codiak Biosciences, Inc, Pfizer Inc., Infinity Pharmaceuticals Inc., InterVenn Biosciences, Jounce Therapeutics, Inc., Phenomic AI, Phenomic AI, Marker Therapeutics, Oncolytics Biotech, C-Reveal Therapeutics, Two Bear Capital, Celgene Corporation, Oncolytics Biotech, Catalio Capital Management, Affini-T, Lytix Biopharma, Achelois Pharmaceuticals, Lytix Biopharma, Hengenix, Becton Dickinson, Candel Therapeutics, Illumina, Inc.	IC, IC, IC, IC, IC, IC, S, IC, IC, IC, IC, IC, IC, SO, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, S, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC	Program Committee, Speaker
Smith	Melody	No Relationships		Speaker
Sullivan	Ryan	Bristol-Myers Squibb, Merck, Pfizer, Merck, Novartis	IC, IC, IC, GC, IC	Program Committee, Speaker
Tran	Eric	Society for Immunotherapy of Cancer, AstraZeneca, PACT Pharma, , PACT Pharma, Turnstone Biologics, , Turnstone Biologics	GC, IC, SO, P, IC, SO, P, IC	Speaker
Turley	Shannon	Genetech	E	Speaker
Wainberg	Zev	Amgen, Astra Zeneca, Daiichi, Bayer, BMS, Merck, Ipsen, Five Prime, Gilead, Arcus, Astellas, Molecular Templates, Array	IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC	Speaker



AACR Special Conference Tumor Immunology and Immunotherapy

October 21-24, 2022 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Wargo	Jennifer	Omniprex, Roche/Genentech, Exelixis, Bristol Myers Squibb Company, Bristol Myers Squibb Company, Physician Education Resource, OSE therapeutics, Imedex, Novartis, Everimmune, Micronoma, OSE therapeutics, Merck, MedImmune, LLC, AstraZeneca, PeerView, Illumina, Gilead Sciences, GlaxoSmithKline, Dava Oncology, Micronoma	IC, FO, IC, FO, IC, IC, FO, IC, FO, FO, FO, S, FO, IC, FO, IC, IC, IC, FO, IC, S	Program Committee, Speaker
Wolchok	Jedd	Apricity	SO	Program Committee
Zappasodi	Roberta	Patent, Bristol-Myers Squibb INHIBITION OF CTLA-4 AND/OR PD-1 FOR REGULATION OF T CELLS. Inventor. U.S. Provisional Patent: WO2019094352A1. https://pubchem.ncbi.nlm.nih.gov/patent/US-2021179714-A1 . ANTIBODIES AND METHODS OF USE THEREOF. Inventor. U.S. Provisional Patent Application: WO2018106864A1. https://pubchem.ncbi.nlm.nih.gov/patent/US-2020024350-A1 . ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF. Inventor. US Patent Application US10323091B2. https://pubchem.ncbi.nlm.nih.gov/patent/US-10450373-B2 . ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF. Inventor. Patent Application US20180244793A1. https://pubchem.ncbi.nlm.nih.gov/patent/US-2018244793-A1 .	P, GC	Program Committee, Speaker

All of the relevant financial relationships listed for these individuals have been mitigated.